In vivo serotonin 1A receptor hippocampal binding potential in depression and reported childhood adversity

Elizabeth A. Bartlett¹,²*, Ashley A. Yttredahl¹,² ©, Maura Boldrini¹, Andrea E. Tyrer³,⁴, Kathryn R. Hill⁵ ©, Mala R. Ananth⁶ ©, Matthew S. Milak¹,², Maria A. Oquendo⁶, J. John Mann¹,²,⁷, Christine DeLorenzo³,⁸ © and Ramin V. Parsey³,⁸,⁹

¹Department of Psychiatry, Columbia University Irving Medical Center, New York, New York 10032, USA; ²Molecular Imaging and Neuropathology Division, New York State Psychiatric Institute, New York, New York 10032, USA; ³Department of Psychiatry, Stony Brook Medicine, Stony Brook, NY 11794, USA; ⁴Clinical Genetics Research Program, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario M5S, Canada; ⁵National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, Maryland 20892, USA; ⁶Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; ⁷Department of Radiology, Columbia University, New York, New York 10027, USA; ⁸Department of Biomedical Engineering, Stony Brook University, Stony Brook, New York 11794, USA and ⁹Department of Radiology, Stony Brook University, Stony Brook, New York 11794, USA

Abstract

Background. Reported childhood adversity (CA) is associated with development of depression in adulthood and predicts a more severe course of illness. Although elevated serotonin 1A receptor (5-HT₁A(R)) binding potential, especially in the raphe nuclei, has been shown to be a trait associated with major depression, we did not replicate this finding in an independent sample using the partial agonist positron emission tomography tracer [¹¹C]CUMI-101. Evidence suggests that CA can induce long-lasting changes in expression of 5-HT₁A,R, and thus, a history of CA may explain the disparate findings.

Methods. Following up on our initial report, 28 unmedicated participants in a current depressive episode (bipolar n = 16, unipolar n = 12) and 19 non-depressed healthy volunteers (HVs) underwent [¹¹C]CUMI-101 imaging to quantify 5-HT₁A,R binding potential. Participants in a depressive episode were stratified into mild/moderate and severe CA groups via the Childhood Trauma Questionnaire. We hypothesized higher hippocampal and raphe nuclei 5-HT₁A,R with severe CA compared with mild/moderate CA and HVs.

Results. There was a group-by-region effect (p = 0.011) when considering HV, depressive episode mild/moderate CA, and depressive episode severe CA groups, driven by significantly higher hippocampal 5-HT₁A,R binding potential in participants in a depressive episode with severe CA relative to HVs (p = 0.019). Contrary to our hypothesis, no significant binding potential differences were detected in the raphe nuclei (p-values > 0.05).

Conclusions. With replication in larger samples, elevated hippocampal 5-HT₁A,R binding potential may serve as a promising biomarker through which to investigate the neurobiological link between CA and depression.

Introduction

Bipolar depression (BD) and major depressive disorder (MDD) are among the leading causes of disability worldwide [1]. Reported childhood adversity (CA) is a predictor of lifetime risk for MDD [2] and is associated with poorer prognosis in both MDD and BD [3, 4]. Aberrations of the serotonergic system, strongly implicated in the diathesis of depression [5], may be a result of CA and may moderate the relationship between adversity and onset and progression of depressive symptomatology [6, 7].

More than other types of negative life events, CA is associated with depressive disorders [2]. Reported CA has a high prevalence in adults with mood disorders [8], and episodes of adversity have a cumulative effect on the risk for depression in adulthood [9]. CA plays a large role in clinical outcomes as well [10], predicting an earlier age of onset of MDD and BD, more persistent and frequent depressive episodes, and increased risk for suicide attempts [3, 4].

One possible mechanism by which CA influences depression and its severity is through the serotonin system, including increases in serotonin 1A receptor (5-HT₁A,R) density [10–12]. Alterations in positron emission tomography (PET)-measured 5-HT₁A,R binding potential can predict antidepressant treatment efficacy in both BD and MDD [13, 14]. Animal research has shown
altered 5-HT1A-R expression following early life adversity [15, 16, 17, 18]. Glucocorticoid-induced down-regulation of the 5-HT1A-R occurs across the lifespan, likely an adaptive response to stress [19]. However, evidence suggests that there is a critical developmental window early in life during which exposure to stress can induce more enduring changes in 5-HT functioning [11, 12, 20–22]. In rodents exposed to early life stress, there have been reports of both increases in 5-HT1A-R density in the hippocampus [18] and attenuated 5-HT1A-R mRNA expression [21, 23] and 5-HT1A-R binding [24]. Nonhuman primates with early life stress had lower 5-HT1A-R density [25] and lower 5-HT1A-R binding [15]. Rodents exposed to early life stress have also been shown to develop anxious and depressive-like phenotypes in adulthood with increased hippocampal 5-HT1A-R density [20]. Differing models of early life stress in rodent and nonhuman primate work (e.g., time of maternal deprivation and animal age) may contribute to the mixed findings.

In humans, postmortem work reports higher 5-HT1A-R density in suicide decedents with a history of CA compared to healthy volunteers (HVs), suicide decedents without a history of adversity, and nonsuicide decedents with a history of adversity [26]. Critically, CA may reduce the efficacy of pharmaceuticals that target the serotonin system [16] via upregulation of the 5-HT1A-R in the hippocampus [27] and might explain why both higher 5-HT1A-R binding [28] and a history of CA [4] predict antidepressant treatment resistance.

Studies using PET to quantify 5-HT1A-R binding potential in MDD and BD have reported different results, largely due to differences in quantification methods [29, 30]. Studies reporting binding potential with reference to the free plasma concentration (BPf), which has been the standard in our group, have most commonly found elevated 5-HT1A-R binding in currently depressed and euthymic patients with MDD and BD relative to HVs [13, 28–34]. Conversely, many studies reporting alternate binding potentials have found lower 5-HT1A-R binding in depression [35–38]. When we considered the alternate binding potential, BPND, which is in reference to the nondisplaceable radioligand in tissue [39], we reconciled these discrepant findings and found lower 5-HT1A-R binding in not recently medicated participants with MDD relative to HVs [29]. However, due to the group differences found in reference region uptake [29], we maintain the use of BPf as our standard outcome measure for 5-HT1A-R quantification. With this, in Ananth et al. [40], although we found that 5-HT1A-R BPf predicted clinical response to lithium treatment for BD, there were no differences between HVs and participants with BD. The analyses reported herein were conducted using an overlapping dataset to Ananth et al. [40] as a follow-up to evaluate whether CA could explain part of the unexpected null result.

We examined the relationship between CA and 5-HT1A-R binding potential, an index of 5-HT1A-R density (assessed with the PET tracer carbon 11–labeled [O-methyl-(11)C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione[C]11C]CUMI-101) in a transdiagnostic sample of unmedicated participants in a current depressive episode and HVs. We assessed 5-HT1A-R binding in the hippocampus because of the sensitivity of this region to early life stress [15, 19, 20, 41, 42]. In addition, we assessed binding in the raphe nuclei because it is the primary site of serotonin synthesis [43, 44]. Further, 5-HT1A-Rs in this region are autoreceptors that regulate serotonin neuron firing and release and may mediate the antidepressant action of selective serotonin reuptake inhibitors for depression [14]. We hypothesized that differences in 5-HT1A-R binding potential between participants in a depressive episode and HVs would be driven by CA, such that participants reporting severe CA would also have the highest 5-HT1A-R binding potential.

**Materials and Methods**

**Participants**

Twenty-eight participants in a current depressive episode (BD: n = 16, MDD: n = 12), and 19 non-depressed HVs were included in this analysis and overlap with participants from two other previously reported studies [40, 45]. All bipolar participants from Ananth et al. [40] were used here, except the four participants missing Childhood Trauma Questionnaire (CTQ) data from that study. The hypotheses regarding CA were secondary to the main grant (National Institutes of Mental Health R01MH090276). Data could be made available by request to Dr. Ramin V Parsey. Study procedures were approved by Institutional Review Boards at Brookhaven National Laboratory (BNL), Yale University Medical Center (Yale), Stony Brook University (SBU), and Columbia University Irving Medical Center (CIUCM), and written informed consent was obtained from all participants. Participants were anonymized after intake and assigned unique study identification numbers.

Patients were aged 18–70 years, in a current major depressive episode (scores ≥15 on the 17-item Hamilton Depression Rating Scale (HDRS-17) [46]), and free of psychotropic medications for at least 3 weeks prior to PET scans (except benzodiazepines for at least 24 hours, fluoxetine for at least 6 weeks, and serotonin-depleting drugs for at least 3 months prior to PET scans). Participants were diagnosed with either BD or MDD but were free of any other major psychiatric disorders (not including eating disorders or phobias) as assessed using the Structured Clinical Interview for DSM-IV [47]. HVs had no lifetime history of Axis I disorders (except one HV had a history of adjustment disorder 20 years prior), and no first-degree relatives with a history of major depression (for participants under the median age plus one quartile for depression onset: 44 years), schizophrenia, suicide attempt, or ≥2 first-degree relatives with a history of substance dependence (for participants under 27 years old). All participants were free of recent alcohol or substance dependence (except for cannabis) for the past 6 months, current substance abuse for the past 2 months, intravenous drug use in the past 5 years, and use of ecstasy more than 15 times in the past 10 years or any use in the month prior to scans.

Participants completed the HDRS-17 and Hamilton Anxiety Scale (HAM-A) [48]. CA was assessed using the CTQ [49], and the combined sample of currently depressed participants with MDD and BD was divided into those who reported severe adversity (n = 21, comprising 10 MDD participants and 11 BD participants) or no, low, or moderate adversity (n = 7, comprising 2 MDD participants and 5 BD participants) based on score classifications in the CTQ manual (see Supplementary Table S1) [49]. Two patients reported moderate adversity, four patients reported low adversity, and one patient reported no adversity; therefore, the no, low, or moderate category will be referred to as “mild/moderate CA” herein. Of the HVs, six patients reported low CA and 13 reported no CA. The CTQ was on average 0.4 ± 59.2 days before the PET scan (max 154 days before, max 227 days after). We did not require close proximity of the CTQ to the PET scan given excellent CTQ stability despite changes in psychopathology levels [50].
Log-transformed 5-HT₁₉R BPₜ data (used to stabilize between-region variances) were checked for normality and the absence of outliers. The impact of CA on 5-HT₁₉R BPₜ was analyzed with a LME model. Log-transformed BPₜ was the model outcome with fixed effects of brain region (raphe nuclei and hippocampus), group (HV, mild/moderate CA, severe CA), and sex, and participant fit as a random effect. The interaction effect of group–by–region was also fit. BPₜ values were weighted using the individual SEs, as 1/SE². Reported percent differences between groups were computed using means weighted according to this method. Both within- and between-participant covariances were modeled using unstructured variance and random intercepts, and residual maximum likelihood was used for model fitting. A second, two-group LME was also fit comparing HVs to the full sample of all participants currently in a depressive episode (not splitting by CA status, with BD and MDD combined). Convergence criteria were met for the models reported. These analyses were performed using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).

Site was excluded from both primary and secondary analyses as a fixed factor due to group imbalance (all patient scans were acquired at Yale). However, sensitivity analyses were conducted by repeating the LMEs for the subset of participants who underwent their PET scans at Yale (n = 42) (see Supplementary Materials and Supplementary Figure S1).

Results
Participants in a depressive episode and HVs did not significantly differ in age or sex (Table 1), and no significant group differences were present in these variables when participants were grouped by CA severity (depressive episode with mild/moderate CA [n = 7], depressive episode with severe CA [n = 21], and HVs [n = 19]; Table 2). Injected dose, injected mass, specific activity, and mean free fraction in blood plasma (fb) also did not differ significantly between groups (see Supplementary Table S2). No significant differences were observed between depressive episode groups on other clinical measures including ratings of anxiety, depression, or suicidality, except for CTQ scores, as expected (Table 2).

A priori analyses
The effect of CA on 5-HT₁₉R BPₜ significantly differed by brain region (F = 5.08, p = 0.011). This was driven primarily by an elevation of 25.7%, on average, in hippocampal 5-HT₁₉R BPₜ in participants with severe CA compared with HVs (t = 2.43, p = 0.019; Figures 1 and 2). There was no significant main effect of CA on 5-HT₁₉R BPₜ across brain regions (F = 0.42, p = 0.66), and no differences were observed in BPₜ between any pair of groups in the raphe nuclei, nor in the hippocampus between the mild/moderate adversity and severe adversity depressive episode groups (p-values > 0.05). There was a significant main effect of sex (female > male, F = 4.10, p = 0.049), included as a control variable. There was a significant region-specific effect of HV versus all participants in a depressive episode (MDD and BD combined) on 5-HT₁₉R BPₜ (F = 10.10, p = 0.003). This was driven by a significant elevation of 24.3%, on average, in hippocampal 5-HT₁₉R BPₜ in participants in a depressive episode compared to HVs (F = 2.48, p = 0.017). Further analyses splitting participants in a depressive episode into MDD and BD groups are included in Supplementary Materials. This indicates an effect of depressive episode on hippocampal 5-HT₁₉R BPₜ, but also given the stepwise nature of highest

Statistical analyses
Differences in age, HDRS-17, and Beck’s Depression Inventory (BDI) [60] between the three groups (HV, participants in a depressive episode with mild/moderate CA, participants in a depressive episode with severe CA) were analyzed using a one-way analysis of variance (ANOVA), and significant effects were followed up with independent samples t-tests. Differences in HAM-A and CTQ between the mild/moderate and severe CA depressive episode groups and in HDRS-17, BDI, and age between HVs and participants in a depressive episode were assessed using independent samples t-tests. Pearson’s chi-squared test was used to assess group differences in sex distributions. All demographic analyses were conducted in R, version 3.5.3 (R Core Team).

Scanning procedure
Image acquisition and analysis
[¹¹C]CUMI-101 PET imaging and analysis were performed as previously described [45]. All participants underwent a 120-minute [¹¹C]CUMI-101 PET scan, acquired on either an ECAT EXACT HR+ (Yale n = 42 and BNL n = 4) or ECAT HR+ (CUMIC n = 1) (Siemens CTI Molecular Imaging, Knoxville, TN, USA) [40, 45]. Following a 10-minute transmission scan, [¹¹C]CUMI-101 was injected as an intravenous bolus (injected dose = 14.65 ± 4.57 mCi; specific activity = 5.20 ± 3.97 mCi/nmol). Automated arterial blood sampling was performed for the first 7 minutes of PET acquisition, with manual sampling thereafter. As previously described, the full arterial sampling data were used to generate a metabolite-corrected input function [45]. In the 13 cases without full arterial sampling data, a simultaneous estimation algorithm validated for [¹¹C]CUMI-101 was used to compute the metabolite-corrected input function with the solution constrained by a single venous or arterial blood sample [51–53].

Motion correction was performed via frame-by-frame rigid body registration to a reference frame. The mean of the motion-corrected frames was then co-registered to the participant’s MRI [45]. The a priori hippocampus and raphe nuclei regions were delineated as previously described [45, 54, 55] (raphe nuclei mask available at https://renaissance.stonybrookmedicine.edu/psychiatry/research/cubit/data). These delineations were used to create regional time activity curves. Exploratory volumetric analyses were performed using Freesurfer 5.3 (http://surfer.nmr.mgh.harvard.edu/) to automatically segment the whole hippocampus and its subfields [56], following a visual inspection of intermediate pre-processing steps [57], to ensure BPₜ differences were not influenced by volume differences between groups.

Likelihood estimation in graphical analysis (LEGA) was used to obtain the optimal [¹¹C]CUMI-101 outcome measure BPₜ = Bavail / Kᵰ (concentration of available receptors) / KD (radiotracer equilibrium dissociation constant), that is, the ratio of the concentration of specifically bound [¹¹C]CUMI-101 in tissue to the concentration of free [¹¹C]CUMI-101 in blood plasma at equilibrium) from the hippocampus and raphe nuclei time activity curves [39, 58]. BPₜ is expressed in units of mL/cm³, that is, if BPₜ = 5 mL/cm³, then 5 mL of plasma would be required to account for [¹¹C]CUMI-101 in 1 cm³ of brain tissue [39]. The plasma-free fraction (fb) across participants was 37% ± 7%. Standard errors (SE) were computed via resampled residuals bootstrapping of the LEGA fits [59]. A better fit of the time activity curve corresponds to lower SE and therefore heavier weighting of that participant’s 5-HT₁₉R BPₜ data in the linear mixed-effects (LME) models.

Statistical analyses
Differences in age, HDRS-17, and Beck’s Depression Inventory (BDI) [60] between the three groups (HV, participants in a depressive episode with mild/moderate CA, participants in a depressive episode with severe CA) were analyzed using a one-way analysis of variance (ANOVA), and significant effects were followed up with independent samples t-tests. Differences in HAM-A and CTQ between the mild/moderate and severe CA depressive episode groups and in HDRS-17, BDI, and age between HVs and participants in a depressive episode were assessed using independent samples t-tests. Pearson’s chi-squared test was used to assess group differences in sex distributions. All demographic analyses were conducted in R, version 3.5.3 (R Core Team).
regions, we analyzed an additional 11 brain regions that comprise the original LME, which was not significant (effect, we added a three-way interaction of region-by-sex-by-CA in different between males and females (post-hoc tests confirmed this lack of sex effect with the severe CA, followed by mild/moderate CA, and then HV, it may indicate a dependence of 5-HT<sub>1A</sub>R BP<sub>F</sub> on CA in depressive disorders.

**Exploratory analyses**

For participants in a depressive episode, the continuous summed score across the CTQ subscales was not significantly associated with 5-HT<sub>1A</sub>R BP<sub>F</sub> (F = 0.20, p = 0.66), nor was there a region-specific effect (F = 0.12, p = 0.73). When HVs were added, a significant continuous CTQ-by-region effect (F = 5.11, p = 0.03) was present; however, the correlation between CTQ summed over the five subscales and 5-HT<sub>1A</sub>R BP<sub>F</sub> was not significant for either region alone (hippocampus: B = 0.001, t = 0.79, p = 0.43; raphe nuclei: B = −0.002, t = −1.17, p = 0.24).

To test for a potential sex difference in the severe CA versus HV effect, we added a three-way interaction of region-by-sex-by-CA in the original LME, which was not significant (F = 0.39, p = 0.68). Post-hoc tests confirmed this lack of sex effect with the severe CA versus HV effect in the hippocampus not being significantly different between males and females (B = 0.07, t = 0.52, p = 0.60).

Extending beyond the a priori hippocampal and raphe nuclei regions, we analyzed an additional 11 brain regions that comprise the full set of brain regions used in prior studies on the 5-HT<sub>1A</sub>R from our group [13, 31, 33, 40, 61, 62]. The effect of CA on 5-HT<sub>1A</sub>R BP<sub>F</sub> again significantly differed by brain region (F = 1.97, p = 0.004), with the post-hoc significant effect of hippocampal 5-HT<sub>1A</sub>R BP<sub>F</sub> in participants with severe CA versus HVs remaining and additionally a significant elevation of 17.0% in parahippocampal gray matter volume and the parahippocampal gyrus 5-HT<sub>1A</sub>R BP<sub>F</sub> in participants with severe CA versus HVs (t = 0.22, p = 0.005).

An ANOVA found no evidence of group differences in hippocampal gray matter volume (F = 0.778, p = 0.67), and hippocampal gray matter volume was not correlated with SE-weighted BP<sub>F</sub> values across groups (r = 0.05, p = 0.72). Further exploratory analyses on hippocampal subfields were performed and found no significant differences between groups (Supplementary Tables S3 and S4).

**Discussion**

This is the first PET study, to our knowledge, to directly assess the relationship between reported CA and 5-HT<sub>1A</sub>R binding potential in depressive episodes using the weak partial agonist tracer, [<sup>11</sup>C] CUMI-101. Participants in a current depressive episode who reported severe CA had higher hippocampal 5-HT<sub>1A</sub>R BP<sub>F</sub> than HVs. If this finding is replicated in a larger sample, it could be used...
Contrary to our hypothesis, we did not observe a difference in raphe nuclei 5-HT$_{1A}$R BP$_F$ between groups based on CA history. The raphe nuclei are the sites of 5-HT synthesis and release [43, 44], and 5-HT$_{1A}$ raphe nuclei autoreceptors regulate 5-HT neurotransmission throughout the brain by controlling serotonin neuron firing and release [66]. Evidence of 5-HT$_{1A}$R involvement in CA response has been mixed in the hippocampus and raphe nuclei. In the hippocampus, acute and chronic corticosterone [67, 68] and acute stress [69] have been shown to reduce 5-HT$_{1A}$R binding and mRNA levels in rodents, possibly through multiple transcriptional repression mechanisms involving both glucocorticoid and mineralocorticoid receptors [70, 71]. In the raphe nuclei, differences in 5-HT$_{1A}$R function [72], 5-HT synthesis [73], and 5-HT$_{1A}$R mRNA expression [74] were found in rodents with early life stress. Bravo et al. [75] found that maternal separation reduced 5-HT$_{1A}$R mRNA expression in the raphe nuclei, with no change in the hippocampus, and Vázquez et al. [76] found the opposite, with maternal separation elevating 5-HT$_{1A}$R mRNA expression in the raphe nuclei, with no change in the hippocampus. It is possible that after CA, during the transition to adulthood, there is a compensatory induction of 5-HT$_{1A}$R that results in increased hippocampal 5-HT$_{1A}$R, but a full-time course has yet to be reported.

There are a few factors that may account for our findings. First, there was an effect of sex on the results of those studies. Although our small sample size prevented us from fully being able to test interaction effects with sex, there was a main effect of sex in both of our statistical models. Future research could be done with a larger sample to test for sex-dependent effects of CA on 5-HT$_{1A}$R binding potential in the raphe nuclei.

Second, prior studies did not look for dose-dependent effects of CA. While we found a significant difference in hippocampal 5-HT$_{1A}$R between participants in a depressive episode reporting severe CA and HVs, visual inspection of group means also suggests a potential stepwise effect of reported CA on 5-HT$_{1A}$R BP$_F$ (Figure 2). It is possible that the small size of our mild/moderate CA group limited our ability to detect significance in post-hoc effects with the severe adversity and HV groups statistically, and further research is warranted. Differences in 5-HT$_{1A}$ autoreceptor functioning in the raphe nuclei may represent a prepotent vulnerability that, in the context of CA, can lead to depression. Evidence suggests that there is a critical developmental period during which early stress can lead to long-term changes in 5-HT$_{1A}$R density in projection targets such as the hippocampus [21]. Further, these changes appear to result in reduced plasticity of the serotonergic system that, when combined with stress in adulthood, could result in stress-related psychiatric morbidities such as depression [74]. More research on the interaction between CA and 5-HT$_{1A}$ in the raphe nuclei is needed to understand how early life experiences contribute to the development of depressive disorders.

Finally, $^{[1]}$C]-WAY100635 is a 5-HT$_{1A}$R antagonist and as such binds 5-HT$_{1A}$R independent of whether they are in the high or low affinity state, whereas the currently used $^{[1]}$C]-CUMI-101 has been shown to be a partial agonist in $^{[35]}$S]GTP$_{gS}$ binding studies in human 5-HT$_{1A}$-transfected Chinese Hamster Ovary cells [77], but also has functional antagonist activity in cross-species examination [78]. Differences between $^{[1]}$C]-WAY100635 and $^{[1]}$C]-CUMI-101 conformational binding preference may explain the low binding in the raphe nuclei with $^{[1]}$C]-CUMI-101 [34, 45] relative to $^{[1]}$C]-WAY100635 [31, 61, 62], which could contribute to why we did not observe an effect of depression on 5-HT$_{1A}$R binding in the raphe nuclei, but did in the hippocampus. The raphe nuclei are also populated with autoreceptors and the hippocampus...
heteroreceptors, with documented differences in 5-HT_{1A}R signaling between the regions [79], which could also account for the disparate findings.

While studies using [^{11}C]-WAY100635 have consistently found depressed versus HV differences in raphe nuclei 5-HT_{1A}R [31, 33, 37], the [^{11}C]-CUMI-101-measured difference in 5-HT_{1A}R binding here seems to be limited to the hippocampus. Two recent analyses with [^{11}C]-CUMI-101 found differences in 5-HT_{1A}R binding potential between BD and HV groups in the raphe nuclei and across a large set of regions of interest (ROIs) that included the hippocampus [34] and between a mixed-mood disorder sample at high risk for mood disorder comprising participants with MDD, BD, dysthymia, and depressive disorder not otherwise specified and HVs in the ventromedial prefrontal cortex and the medial orbitofrontal cortex [80]. However, in Ananth et al. [40], there were no differences between BD and HV groups in the raphe nuclei or in a large set of ROIs [40]. The current study used the participants from Ananth et al. [40] with BD who completed the CTQ. We found here hippocampal differences between a combined BD + MDD group and HVs; however, we also found that when BD and MDD groups were compared in separate models to HVs, this difference did not persist (Supplementary Materials). We theorize that the discordance with Ananth et al. [40] may be due to increased power here to detect an effect given the combined BD + MDD sample relative to the sole BD sample in Ananth et al. [40], along with differences within the HV group. Studies with larger samples could test this theory. However, it is worth noting that the two regions of significant elevation in participants in a depressive episode with severe CA relative to HV, the hippocampus (a priori) and parahippocampus (exploratory), were two of the three brain regions in Ananth et al. [40] whose 5-HT_{1A}R BP_{F} predicted lithium monotherapy treatment response. It may be that these two regions are particularly sensitive to effects that both contribute to the pathogenesis and ameliorate the progression of depressive disorders.

There are limitations to this study. First, our modest sample size included a set of HVs imaged at alternate sites (BNL, n = 4 and CUIMC, n = 1). However, we repeated our analyses and our findings persisted when only including those scanned at Yale (See Supplementary Materials). Although we did control for the effect of sex on 5-HT_{1A}R binding potential (female > male), it is possible that the mild/moderate CA group’s lower 5-HT_{1A}R binding potential than the severe CA group was driven by the mild/moderate CA group not being well matched for sex, with only two of the seven participants being female. Further, there have been mixed findings regarding age effects on 5-HT_{1A}R with some studies reporting no association [29] and others showing 5-HT_{1A}R binding potential decreases with age, particularly in females, in humans [81, 82] and nonhuman primates [83]. Although age effects in this study did not reach statistical significance, it is possible that the limited sample size and age range inhibited us from detecting an effect.

Second, the CTQ is a retrospective self-report questionnaire and subject to recall bias, especially in participants with depression. However, it is a sensitive and valid screening tool for assessment of CA in psychiatric settings [84]. Participants were grouped by severity of CA based on the CTQ manual [49]. This method classifies individuals reporting severe abuse or neglect in at least one CTQ domain as having experienced severe adversity but does not account for a cumulative effect of adversity across multiple domains. Although scores are influenced by several dimensions of CA [49], the CTQ is unable to capture on a true scale the severity, duration, and subjective experience of adversity [49]. We did perform exploratory analyses on the summed scores across all CTQ domains, treating it as a continuous measure; however, the stepwise increase in 5-HT_{1A}R BP_{F} from HVs to participants in a depressive episode with severe CA was not reflected in the continuous analyses, with no significant correlations between summed CTQ and 5-HT_{1A}R BP_{F} at the regional level.

Third, all but one participant in a depressive episode reported some degree of childhood trauma. Therefore, it was not feasible to assess 5-HT_{1A}R BP_{F} in participants in a depressive episode without CA. However, mild/moderate and severe CA subgroups did not differ on any other symptom measure, suggesting that our results are not confounded by clinical variables such as depression, anxiety, or suicidality. Furthermore, the high frequency of CA in our depressive episode sample is consistent with the marked relationships between early adversity and BD and MDD that have been reported in the literature [4]. However, the lack of continuous correlation between summed CTQ and 5-HT_{1A}R BP_{F} the limited size of the mild/moderate CA group, and the fact that all

---

**Figure 2.** Representative [^{11}C]CUMI-101 voxel maps of BP_{F} (mL/cm³) from each group, highlighting the hippocampus (A) and raphe nuclei (B). All images shown in Montreal Neurological Institute (MNI) space. Template MRI shown at left and a representative participant’s PET voxel map from each group shown in the right three columns.
participants in a depressive episode reported CA all combine to limit our ability to disentangle the depression effect from the CA effect. Future studies with larger samples of participants in a depressive episode should seek to clarify these effects.

Lastly, given the cross-sectional nature of our investigation, assessment of CA as a causal factor in the development of BD or MDD was beyond the scope of this study. However, these initial results, consistent with previous findings of a relationship between BD or MDD and CA, and in conjunction with the congruent animal studies designed to assess causality described above, support this interpretation.

In summary, this is the first investigation of the relationship between CA and 5-HT₁₆R binding potential using [¹¹C]CUMI-101 PET in currently depressed participants with BD or MDD compared to HVs. The primary finding was that participants in a depressive episode with severe CA had higher hippocampal 5-HT₁₆R BP₁ than HVs. These results suggest an interplay between CA, depressive symptomatology in adulthood, and alterations of 5-HT₁₆R in the hippocampus. Follow-up in larger samples, especially given the small sample size of the mild/moderate CA group, and attempts to assess causality in the link between CA, depression, and the 5-HT₁₆R are necessary. A central 5-HT₁₆R BP₁ biomarker of depression comorbid with CA may have the potential to be applied toward the future development of interventions for prevention and treatment of depressive disorders.

Supplementary Materials. To view supplementary material for this article, please visit http://doi.org/10.1192/j.eurpsy.2023.4.

Acknowledgments. We would like to thank the study coordinators Kristin Kolb, Sunia Choudhury, Kalyn Gruenfelder, Robert Lopez, Meghan Leonard, and study nurse practitioners Sally South and Colleen Oliver. We would also like to thank Brookhaven National Laboratory and the Yale PET Center for radiotracer synthesis, PET scanning, and blood analysis. Finally, we thank the Center for Understanding Biology using Imaging Technology (CUBIT) image analysts at SBU for their work in data importing, analysis, and quality control.

Financial Support. This work was supported by The National Institute of Mental Health (R01MH090276, PI: Ramin Parsey, MD, PhD).

Conflicts of interest. Drs Oquendo and Mann receive royalties from the Research Foundation for Mental Hygiene for the commercial use of the Columbia Suicide Severity Rating Scale. Dr. Oquendo owns shares in Mantra, Inc. She serves as an advisor to Alkermes and Fundacion Jimenez Diaz (Madrid). Her family owns stock in Bristol Myers Squibb. The other authors declare none.

Author Contribution. Dr. Parsey was the principal investigator for the study. Drs. DeLorenzo, Mann, Milak, Oquendo, and Parsey designed the study. Drs. Ananth and Bartlett analyzed the neuroimaging data. Drs. Ananth, Bartlett, Hill, Yrther, and Yttredahl performed data analysis. Drs. Bartlett, Yrther, and Yttredahl completed the statistics. Drs. Bartlett, Hill, Tyrer, and Yttredahl drafted the manuscript. All authors contributed to manuscript revision and approved the final manuscript.

References


Zanderigo F, Ogden RT, Mann JJ, Parsley RV. A voxel-based clustering approach for the automatic selection of testing regions in the simultaneous estimation of input functions in PET. NeuroImage. 2010;52:5176.

